Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ADVERSE REACTIONS OF COMPETITOR PRODUCTS FOUND DURING CONTROLLED STUDIES

Executive Summary

ADVERSE REACTIONS OF COMPETITOR PRODUCTS FOUND DURING CONTROLLED STUDIES may be reported instead of to the mfr. if the reaction is a serious one requiring reporting within 15 days, FDA Center for Drugs and Biologics Director Harry Meyer, MD, said in a recently issued Q&A document on the agency's guidelines for postmarketing reporting of adverse drug reactions. The Q&A states that "when adverse events (reactions) are found for a competitor's drug during a controlled study. . . 15-day type reports (serious, unlabeled events or increased frequency of serious labeled events) associated with a competitor's products may be made directly to FDA." However, the guideline clarifications note, "generally, reactions to a competitor's drug should be reported to the manufacturer of the drug." In the case of a controlled study the FDA is making an "allowed exception. . .in order to protect competitive information." In a cover letter to the Q&A, Meyer stated that the postmarketing adverse drug reaction (ADR) reporting guidelines would be redrafted in January 1986. The Q&As, Meyer said, "are bridging statements that are intended to provide interim guidance to applicants." Commenting on the 15-day clock for reporting ADRs, the document states that it starts when the applicant receives information indicating that a reported reaction fulfills the criteria for filing a 15-day report, i.e., that a serious, unlabeled reaction has been received or that a serious, labeled reaction has been reported at increased frequency." If the outcome of an adverse event is unknown "and therefore whether the reaction is serious cannot be determined, the report should be submitted in the periodic report," the document states. "If the reaction is later found to be both serious and unlabeled, the 15-day time period begins with receipt of this follow-up information." If the event(s) occur during a blinded study, the agency continued, "reports should be made only when the code is broken; i.e., within 15-days after the code is broken and serious unlabeled reactions are found." Defining what constitutes a "life-threatening" reaction, the document states that the term "refers to a reaction (event) associated with. . .death, new hospitalization, ]or[ prolonged hospitalization." Thus, a serious reaction "is one that is associated with one or more of the following: death, new hospitalization, prolonged hospitalization, permanent or severe disability, prescription drug therapy, congenital anomaly, cancer, or overdose." Only "overdoses which are associated with adverse reactions (events) need to be reported," the document explains. "If no adverse event occurs, the fact alone of overdose need not be reported. If the resultant or associated reaction is unlabeled, then a 15-day report must be filed; if labeled, then the report is filed within the periodic report."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel